Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Behcet Syndrome
|
243 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.830 | 0.800 | 5 | 2010 | 2017 | |||||
Oral Ulcer
|
101 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
Breast Carcinoma
|
2793 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.040 | 0.750 | 4 | 2012 | 2018 | |||||
Malignant neoplasm of breast
|
3417 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.040 | 0.750 | 4 | 2012 | 2018 | |||||
Malignant neoplasm of stomach
|
615 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.040 | 1.000 | 4 | 2011 | 2019 | |||||
Stomach Carcinoma
|
652 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.040 | 1.000 | 4 | 2011 | 2019 | |||||
Alzheimer's Disease
|
1843 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2007 | 2016 | |||||
cervical cancer
|
268 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2015 | 2016 | |||||
Cervix carcinoma
|
283 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2015 | 2016 | |||||
Coronary Artery Disease
|
1577 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2015 | 2018 | |||||
Crohn Disease
|
1147 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2009 | 2016 | |||||
Diabetes Mellitus, Non-Insulin-Dependent
|
2672 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2010 | 2014 | |||||
Diabetic Nephropathy
|
238 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2014 | 2018 | |||||
Diffuse Large B-Cell Lymphoma
|
127 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2015 | 2017 | |||||
Esophageal carcinoma
|
272 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 0.500 | 2 | 2015 | 2016 | |||||
Esophageal Neoplasms
|
270 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 0.500 | 2 | 2015 | 2016 | |||||
Human papilloma virus infection
|
42 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2015 | 2019 | |||||
Irritable Bowel Syndrome
|
52 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 0.500 | 2 | 2013 | 2019 | |||||
Leukemia, Myelocytic, Acute
|
6892 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2015 | 2018 | |||||
Lip and Oral Cavity Carcinoma
|
172 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2008 | 2016 | |||||
Lymphoma, Non-Hodgkin
|
197 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2010 | 2015 | |||||
Malignant neoplasm of esophagus
|
214 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 0.500 | 2 | 2015 | 2016 | |||||
Malignant neoplasm of mouth
|
184 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2008 | 2016 | |||||
Malignant Neoplasms
|
1641 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2010 | 2013 | |||||
Malignant tumor of cervix
|
245 | 0.508 | 0.800 | 1 | 206773289 | 5 prime UTR variant | A/G | snv | 0.69 | 0.020 | 1.000 | 2 | 2015 | 2016 |